Fig. 8

The effect of MSCs/rTGF-β on the phagocytic ability of RAW264.7 cells was tested by flow cytometry. a, b RAW264.7 cells were treated with or without AS1842856 (10 nM)/GSK2141795 (30 μmol/l), followed by stimulation with LPS (500 ng/ml) or rTGF-β (10 ng/ml)/MSCs for 48 h. The results are presented as the mean ± SD (n = 3). ***p < 0.001 vs. LPS group; ###p < 0.001 vs. LPS+rTGF-β group. AS1842856, FoxO1 inhibitor; FITC, fluorescein isothiocyanate; GSK2141795, Akt inhibitor; LPS, lipopolysaccharide; MSCs, mesenchymal stem cells; rTGF-β, recombinant TGF-β; TGF-βRi, TGF-β receptor inhibitor